Published Studies Related to Glyburide and Metformin (Glyburide / Metformin)
Well-designed clinical trials related to Glyburide and Metformin (Glyburide / Metformin)
Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study. [2007.05]
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. [2006.12.07]
Investigation of the pharmacokinetic and pharmacodynamic interactions between memantine and glyburide/metformin in healthy young subjects: a single-center, multiple-dose, open-label study. [2005.10]
PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. [2005.09]
Well-designed clinical trials possibly related to Glyburide and Metformin (Glyburide / Metformin)
A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. [2008.10]
The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. [2008.06]
Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. [2007.08]
Simultaneous assay of metformin and glibenclamide in human plasma based on extraction-less sample preparation procedure and LC/(APCI)MS. [2007.07.01]
Oral antidiabetic agents in pregnancy and lactation: a paradigm shift? [2007.07]
Oral Antidiabetic Agents in Pregnancy and Lactation: A Paradigm Shift? (July/August). [2007.05.29]
[ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?] [2007.01]
Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. [2007]
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. [2006.12]
Insulins and oral hypoglycemic agents in pregnancy. [2006.11]
Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. [2006.10]
The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptor-gamma/alpha agonist-induced edema in type 2 diabetic patients. [2006.09]
Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. [2006.08]
An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. [2006.08]
Beta-cell response to metformin-glibenclamide combination tablets (Glucovance) in patients with type 2 diabetes. [2006.07]
Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. [2006.03]
Improving metabolic control leads to better working memory in adults with type 2 diabetes. [2006.02]
Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes. [2006.01]
Other research related to Glyburide and Metformin (Glyburide / Metformin)
Cardiovascular, metabolic and hormonal responses to the progressive exercise performed to exhaustion in patients with type 2 diabetes treated with metformin or glyburide. [2008.03]
Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. [2007.11]
Other possibly related research studies
[Probability of control of the patient with diabetes exclusively treated with pharmacological therapy] [2006.07]
Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study. [2006.06]
Diet and medical therapy in the optimal management of gestational diabetes mellitus. [2006]
Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. [2006.11]
Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes. [2006.04]
Apparent resolution of type 2 diabetes mellitus after initiation of potent antiretroviral therapy in a man from Africa with HIV infection. [2006.05.15]
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. [2006.01.17]
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. [2005]
Willingness to pay for inhaled insulin: a contingent valuation approach. [2005]
Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. [2006.02.01]
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. [2005.11.23]
Pemphigus vulgaris triggered by glibenclamide and cilazapril. [2005]
Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. [2005]
[Use of oral lipid-lowering drugs in patients with type-2 diabetes mellitus] [2005.04.30]
Evaluation of drug therapy and risk factors in diabetic hypertensives: a study of the quality of care provided in diabetic clinics in Bahrain. [2005.04]
Diabetes mellitus in a domesticated Spanish mustang. [2005.02.15]
Exenatide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus (as an Adjunct to Metformin and/or a Sulfonylurea). [2007]
Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes. [2007.03]
The new clinical trials with thiazolidinediones - DREAM, ADOPT, and CHICAGO: promises fulfilled? [2007.08]
A comparative study of the effects of hypoglycemic agents on serum electrolytes in the diabetic patients. [2007.01]
Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. [2007.03]
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. [2007.11]
Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. [2007.10.17]
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. [2007.09]
Pharmacological management of gestational diabetes: an overview. [2007.07]
Impact of Fixed-Dose Combination Drugs on Adherence to Prescription Medications. [2008.02.21]
Rosiglitazone Associated Fractures in Type 2 Diabetes: An Analysis From ADOPT. [2008.02.05]
Effects of Persea americana Mill (Lauraceae) ["Avocado"] ethanolic leaf extract on blood glucose and kidney function in streptozotocin-induced diabetic rats and on kidney cell lines of the proximal (LLCPK1) and distal tubules (MDBK). [2008.01]
Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. [2008.03.15]
Impact of fixed-dose combination drugs on adherence to prescription medications. [2008.05]
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). [2008.05]
Increased hematocrit and reduced blood pressure following control of glycemia in diabetes. [2008]
New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm. [2008.07]
Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. [2008.06]
Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naive elderly patients with type 2 diabetes. [2008.08]
|
